Modulating	O
metastasis	O
by	O
a	O
lymphangiogenic	O
switch	O
in	O
prostate	B-Cancer
cancer	I-Cancer
.	O

Prostate	B-Cancer
cancer	I-Cancer
dissemination	O
is	O
difficult	O
to	O
detect	O
in	O
the	O
clinic	O
,	O
and	O
few	O
treatment	O
options	O
exist	O
for	O
patients	O
with	O
advanced	O
-	O
stage	O
disease	O
.	O

Our	O
aim	O
was	O
to	O
investigate	O
the	O
role	O
of	O
tumor	B-Cancer
lymphangiogenesis	O
during	O
metastasis	O
.	O

Further	O
,	O
we	O
implemented	O
a	O
noninvasive	O
molecular	O
imaging	O
technique	O
to	O
facilitate	O
the	O
assessment	O
of	O
the	O
metastatic	O
process	O
.	O

The	O
metastatic	O
potentials	O
of	O
several	O
human	O
prostate	B-Cancer
cancer	I-Cancer
xenograft	I-Cancer
models	O
,	O
LAPC	B-Cell
-	I-Cell
4	I-Cell
,	O
LAPC	B-Cell
-	I-Cell
9	I-Cell
,	O
PC3	B-Cell
and	O
CWR22Rv	B-Cell
-	I-Cell
1	I-Cell
were	O
compared	O
.	O

The	O
cells	B-Cell
were	O
labeled	O
with	O
luciferase	O
,	O
a	O
bioluminescence	O
imaging	O
reporter	O
gene	O
,	O
to	O
enable	O
optical	O
imaging	O
.	O

After	O
tumor	B-Cancer
implantation	O
the	O
animals	O
were	O
examined	O
weekly	O
during	O
several	O
months	O
for	O
the	O
appearance	O
of	O
metastases	B-Cancer
.	O

Metastatic	B-Cancer
lesions	I-Cancer
were	O
confirmed	O
by	O
immunohistochemistry	O
.	O

Additionally	O
,	O
the	O
angiogenic	O
and	O
lymphangiogenic	O
profiles	O
of	O
the	O
tumors	B-Cancer
were	O
characterized	O
.	O

To	O
confirm	O
the	O
role	O
of	O
lymphangiogenesis	O
in	O
mediating	O
metastasis	O
,	O
the	O
low	B-Cell
-	I-Cell
metastatic	I-Cell
LAPC	I-Cell
-	I-Cell
9	I-Cell
tumor	I-Cell
cells	I-Cell
were	O
engineered	O
to	O
overexpress	O
VEGF	O
-	O
C	O
,	O
and	O
the	O
development	O
of	O
metastases	B-Cancer
was	O
evaluated	O
.	O

Our	O
results	O
show	O
CWR22Rv	B-Cell
-	I-Cell
1	I-Cell
and	O
PC3	B-Cell
tumor	I-Cell
cell	I-Cell
lines	I-Cell
to	O
be	O
more	O
metastatic	O
than	O
LAPC	B-Cell
-	I-Cell
4	I-Cell
,	O
which	O
in	O
turn	O
disseminates	O
more	O
readily	O
than	O
LAPC	B-Cell
-	I-Cell
9	I-Cell
.	O

The	O
difference	O
in	O
metastatic	O
potential	O
correlated	O
with	O
the	O
endogenous	O
production	O
levels	O
of	O
lymphangiogenic	O
growth	O
factor	O
VEGF	O
-	O
C	O
and	O
the	O
presence	O
of	O
tumor	B-Multi-tissue_structure
lymphatics	I-Multi-tissue_structure
.	O

In	O
agreement	O
,	O
induced	O
overexpression	O
of	O
VEGF	O
-	O
C	O
in	O
LAPC	B-Cell
-	I-Cell
9	I-Cell
enhanced	O
tumor	B-Cancer
lymphangiogenesis	O
leading	O
to	O
the	O
development	O
of	O
metastatic	B-Cancer
lesions	I-Cancer
.	O

Taken	O
together	O
,	O
our	O
studies	O
,	O
based	O
on	O
a	O
molecular	O
imaging	O
approach	O
for	O
semiquantitative	O
detection	O
of	O
micrometastases	O
,	O
point	O
to	O
an	O
important	O
role	O
of	O
tumor	B-Multi-tissue_structure
lymphatics	I-Multi-tissue_structure
in	O
the	O
metastatic	O
process	O
of	O
human	O
prostate	B-Cancer
cancer	I-Cancer
.	O

In	O
particular	O
,	O
VEGF	O
-	O
C	O
seems	O
to	O
play	O
a	O
key	O
role	O
in	O
prostate	B-Cancer
cancer	I-Cancer
metastasis	O
.	O

